Eisai To Market Aricept At More "Affordable Prices" In China, Larger Asia
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai has begun selling its flagship drug, Aricept, for Alzheimer's disease treatment at "affordable prices" in China and several other Asian countries, a company spokesman said
You may also be interested in...
Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)
Major Japanese pharmas face many of the same problems as major Western pharmas, including patent cliffs and growth slowdown in traditional markets. Japanese pharmas, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News.
Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)
Major Japanese pharmas face many of the same problems as major Western pharmas, including patent cliffs and growth slowdown in traditional markets. Japanese pharmas, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News.
Eisai Seeks Global Approval For Cancer Agent Eribulin As Aricept Patent Expiration Looms Near
TOKYO - Eisai March 31 said it had applied for manufacturing and marketing approval with Japan's Ministry of Health, Labor and Welfare; U.S. FDA and the European Medicines Agency for eribulin for the treatment of locally advanced and metastatic breast cancer